Abstract
A new atypical antipsychotic, brexpiprazole (Rexulti—Otsuka), hasreceived FDA approval as an adjunct treatment to antidepressantsfor major depressive disorder (MDD) and for the treatment of schizophrenia.According to the National Alliance on Mental Illness, approximately6.7% of American adults−about 14.8 million people—live withMDD, and approximately 1.1% of American adults—about 2.4 millionpeople—live with schizophrenia. Therefore, there is a real need foreffective treatments for these conditions.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
